Skip to main content

MESA LABORATORIES INC CO

For the period ended Dec 31, 2024. Filed Feb 4, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2024 · Filed Feb 4, 2025

MLAB$136.91+7.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

M****esa Laboratories, Inc.**

Condensed Consolidated Statements of Cash Flows

(in thousands)

Nine Months Ended December 31,
20242023
Cash flows from operating activities:
Net income$5,140$337
Adjustments to reconcile net income to net cash from operating activities:
Depreciation of property, plant and equipment4,0282,899
Amortization of acquisition-related intangibles13,00222,380
Stock-based compensation expense10,0049,144
Gain on extinguishment of convertible notes(2,887)-
Amortization of step-up in inventory basis1,232-
Foreign currency adjustments2,492(3,128)
Other3,9142,206
Cash from changes in operating assets and liabilities:
Accounts receivable, net918,294
Inventories(539)217
Prepaid expenses and other assets(1,445)(7,841)
Accounts payable(1,919)(1,656)
Accrued liabilities and taxes payable1,879(124)
Unearned revenues(849)(1,478)
Net cash provided by operating activities34,14331,250
Cash flows from investing activities:
Acquisitions, net of cash acquired-(79,700)
Purchases of property, plant and equipment(3,492)(2,032)
Net cash (used in) investing activities(3,492)(81,732)
Cash flows from financing activities:
Proceeds from the issuance of debt, net73,46571,000
Repayment of debt(26,313)(22,000)
Repurchase of convertible debt(71,560)-
Dividends paid(2,598)(2,583)
Other financing, net(1,310)(648)
Net cash (used in) provided by financing activities(28,316)45,769
Effect of exchange rate changes on cash and cash equivalents40727
Net increase (decrease) in cash and cash equivalents2,742(4,686)
Cash and cash equivalents at beginning of period28,21432,910
Cash and cash equivalents at end of period$30,956$28,224
Supplemental non-cash activity:
Right of use assets obtained in exchange for lease liabilities$9,596$4,220

See accompanying notes to Condensed Consolidated Financial Statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.